| Binary pan-cancer classes with distinct vulnerabilities defined by pro-or anti-cancer YAP/TEAD activity JD Pearson, K Huang, M Pacal, SR McCurdy, S Lu, A Aubry, T Yu, ... Cancer Cell 39 (8), 1115-1134. e12, 2021 | 127 | 2021 |
| Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation M Sangwan, SR McCurdy, I Livne-bar, M Ahmad, JL Wrana, D Chen, ... Oncogene 31 (48), 5019-5028, 2012 | 75 | 2012 |
| A CDK2 activity signature predicts outcome in CDK2-low cancers SR McCurdy, M Pacal, M Ahmad, R Bremner Oncogene 36 (18), 2491-2502, 2017 | 42 | 2017 |
| Cancer cells hijack PRC2 to modify multiple cytokine pathways M Abou El Hassan, K Huang, MBK Eswara, M Zhao, L Song, T Yu, Y Liu, ... PLoS One 10 (6), e0126466, 2015 | 37 | 2015 |
| Targeting CDK to prevent and treat retinoblastoma and other cancers SR McCurdy University of Toronto (Canada), 2016 | 2 | 2016 |
| A novel use of E2f and Cdk inhibitors to prevent RB-null tumours in genetically engineered models of retinoblastoma SR McCurdy, A Aman, I Livne-Bar, M Sangwan, D Chen, R Al-awar, ... Cancer Research 72 (8_Supplement), 2590-2590, 2012 | | 2012 |
Jeff WranaSenior Investigator, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto; Professor, Dept. of Mol. Gen., U. of在 lunenfeld.ca 的电子邮件经过验证
